HVTN 312
STUDY BASICS
Are you 18-55 years old and HIV-negative? The HIV Vaccine Trials Network (HVTN) is doing a study to test two experimental HIV vaccines. You may be eligible for this research study to see if the study products are safe, if people are able to take them without becoming too uncomfortable, and how a person’s immune system responds to them.
STUDY PURPOSE
The HIV Vaccine Trials Network (HVTN) is doing a study to test two experimental HIV vaccines.
This study hopes to answer several main questions.
- Are the study products safe to give to people?
- Are people able to take the study products without becoming too uncomfortable?
- How do people’s immune systems respond to the study products? (Your immune system protects you from infections and disease.)
- Does your immune system respond differently if the study products are given at lower or higher amounts?
- After getting the study products, do people develop a certain type of cell in their lymph nodes that researchers think is important for protecting against HIV?
COULD THIS STUDY BE RIGHT FOR YOU?
- 18 to 55 years old
- HIV negative
- In good general health
WHAT PARTICIPANTS CAN EXPECT
You will have about 16 study visits over about 11 months. You will come to the clinic for scheduled visits about 12 times and you will also have about 4 study visits where you do not have to come into the clinic.
Study procedures will include:
- blood draws
- injections
- the collection of white blood cells and cells from your lymph nodes
IRB: STUDY24080005
- National Institutes of Health - HVTN 312, A Phase 1 clinical trial to evaluate the safety and immunogenicity of CH505M5 N197D mRNA-gp160 followed by CH505 TF mRNA-gp160 in adults in overall good health without HIV (Pro00080918)MEET THE RESEARCHER

Madhu Choudhary
Madhu Choudhary is an Associate Professor in the Division of Infectious Diseases in the Department of Medicine at the University of Pittsburgh. A graduate of Maulana Azad Medical College, Dr. Choudhary’s research interests include HIV and viral hepatitis therapeutic clinical trials.